Haematologica (Nov 2024)
Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance
- Marta Anna Sobas,
- Amin T. Turki,
- Angela Villaverde Ramiro,
- Alberto Hernández Sánchez,
- Javier Martinez Elicegui,
- Teresa González,
- Raúl Azibeiro Melchor,
- María Abáigar,
- Laura Tur,
- Daniele Dall'Olio,
- Eric Sträng,
- Jesse M. Tettero,
- Gastone Castellani,
- Axel Benner,
- Konstanze Döhner,
- Christian Thiede,
- Klaus H. Metzeler,
- Torsten Haferlach,
- Frederik Damm,
- Rosa Ayala,
- Joaquín Martínez-López,
- Ken I Mills,
- Jorge Sierra,
- Sören Lehmann,
- Matteo G. Della Porta,
- Jiri Mayer,
- Dirk Reinhardt,
- Rubén Villoria Medina,
- Renate Schulze-Rath,
- Martje Barbus,
- Jesús María Hernández-Rivas,
- Brian J.P Huntly,
- Gert Ossenkoppele,
- Hartmut Döhner,
- Lars Bullinger
Affiliations
- Marta Anna Sobas
- Department of Hematology, Blood Neoplasm and Bone Marrow Transplantation, Wroclaw Medical University
- Amin T. Turki
- Department of Hematology and Oncology, Marienhospital University Hospital, Ruhr-University Bochum, Bochum
- Angela Villaverde Ramiro
- Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Cancer Research Center of Salamanca (USAL-CSIC), Salamanca
- Alberto Hernández Sánchez
- Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Cancer Research Center of Salamanca (USAL-CSIC), Salamanca, Spain; Hematology Department, University Hospital of Salamanca, Salamanca
- Javier Martinez Elicegui
- Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Cancer Research Center of Salamanca (USAL-CSIC), Salamanca
- Teresa González
- Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Cancer Research Center of Salamanca (USAL-CSIC), Salamanca
- Raúl Azibeiro Melchor
- Hematology Department, University Hospital of Salamanca, Salamanca
- María Abáigar
- Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Cancer Research Center of Salamanca (USAL-CSIC), Salamanca
- Laura Tur
- GMV Innovating Solutions, Valencia
- Daniele Dall'Olio
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italia
- Eric Sträng
- Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin
- Jesse M. Tettero
- Department of Hematology, Amsterdam University Medical Center location Vrije Universiteit Amsterdam, Amsterdam, Netherlands
- Gastone Castellani
- Department of Medical and Surgical Sciences - DIMEC, University of Bologna, Bologna
- Axel Benner
- Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg
- Konstanze Döhner
- Department of Internal Medicine III, University Hospital Ulm, Ulm
- Christian Thiede
- Department of Internal Medicine I, University Hospital Dresden, Dresden
- Klaus H. Metzeler
- Department for Hematology, Cell Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig
- Torsten Haferlach
- MLL Munich Leukemia Laboratory, Munich
- Frederik Damm
- Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg
- Rosa Ayala
- Hematology Department, Hospital Universitario 12 de Octubre, Complutense University CNIO Madrid
- Joaquín Martínez-López
- Hematology Department, Hospital Universitario 12 de Octubre, Complutense University CNIO Madrid
- Ken I Mills
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast
- Jorge Sierra
- Hospital Santa Creu Sant Pau, Barcelona
- Sören Lehmann
- Uppsala University Hospital, Uppsala
- Matteo G. Della Porta
- IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy; and Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan
- Jiri Mayer
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University
- Dirk Reinhardt
- Department of Pediatrics III, University Hospital Essen, University Duisburg-Essen, Essen
- Rubén Villoria Medina
- GMV Innovating Solutions, Valencia
- Renate Schulze-Rath
- Bayer AG, Pharmaceuticals Division, Berlin
- Martje Barbus
- AbbVie Deutschland GmbH and Co KG, Wiesbaden
- Jesús María Hernández-Rivas
- Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Hematology Department, University Hospital of Salamanca, Salamanca
- Brian J.P Huntly
- Department of Haematology and Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge
- Gert Ossenkoppele
- Center, Amsterdam UMC,location VUMC, Netherlands
- Hartmut Döhner
- Department of Internal Medicine III, University Hospital Ulm, Ulm
- Lars Bullinger
- Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg
- DOI
- https://doi.org/10.3324/haematol.2024.285805
- Journal volume & issue
-
Vol. 999,
no. 1
Abstract
Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcome of patients with acute myeloid leukemia (AML). However, even before these innovations outcomes with intensive chemotherapy have improved, which has not yet been extensively studied. Thus, we used a large pan-European multicenter dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over two decades. In 5359 AML patients, we compared the impact of intensive induction therapy on outcome over four consecutive 5-year calendar periods from 1997 to 2016. During that time, the 5- year survival of AML patients improved significantly, also across different genetic risk groups. In particular, the 60-day mortality rate has dropped from 13.0% to 4.7% over time. The independent effect of calendar periods on outcome was confirmed in multivariate models. Improvements were documented both for patients
